Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 2;16(3):1021–1030. doi: 10.1111/ajt.13487

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Follow‐up of patient 2. Biochemical follow‐up before and after hepatocyte transplantation. (A) Total serum bilirubin (●) and conjugated serum bilirubin (▴). (B) ALT. (C) Development of de novo PRA to class I and II HLA antigens. Antibodies to HLA B8, B37, B49, B50, DR4, DR7, DR9, DR12, DR52, DR53, and DQ2 were present. HLA antibodies to B8, B50, DR4, DQ2, and DR7 were donor specific. (D) Tacrolimus whole‐blood concentrations. ALT, alanine aminotransferase; Hep‐Tx, hepatocyte transplantation; LTX, liver transplantation; PRA, panel reactive antibodies.